On May 12, 2025, Intrepid Labs announced that it raised US$7 million of Seed funding in a round led by AVANT BIO. The funding will be used for expanding Intrepid Labs’ team, accelerating the development of its proprietary delivery technologies and scaling commercial operations to match the demand.
Intrepid Labs is a biotechnology company that transforms drug formulation development through the use of artificial intelligence.
Osler, Hoskin & Harcourt LLP advised Intrepid Labs with a team consisting of David Jamieson, Jean-Nicolas Delage and Bryan Salazar (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Emerging and High Growth Companies, Montréal
Associate, Emerging and High Growth Companies, Toronto
